May 2014 Edition Vol.11, Issue 5
General Poster Session, Developmental Therapeutics: Immunotherapy, Sunday, June 1, 2014 from 8:00 AM to 11:45 AM. The abstract can be seen at the ASCO Annual Meeting website: here
Poster Highlights Session, Developmental Therapeutics: Immunotherapy, Monday, June 2, 2014 from 1:15 PM to 4:15 PM. The abstract can be seen at the ASCO Annual Meeting website: here
See you in Chicago!
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX®.